Evidence map›Paper›PMID 34539138›Full record

ReviewWorld journal of gastroenterology2021

Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer.

Yong-Bo Kang, Yue Cai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. The hallmarks of host-microbiome decoupling.Frontiers in microbiology · 2026
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Gut microbiota interplay with autophagy-EMT dynamics in colorectal cancer.Frontiers in cell and developmental biology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yong-Bo KangDepartment of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com.
Yue CaiDepartment of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Even though immune checkpoint inhibitors (ICIs) are effective on multiple cancer types, there are still many non-responding patients. A possible factor put forward that may influence the efficacy of ICIs is the gut microbiota. Additionally, faecal microbiota transplantation may enhance efficacy of ICIs. Nevertheless, the data available in this field are insufficient, and relevant scientific work has just commenced. As a result, the current work reviewed the latest research on the association of gut microbiota with ICI treatments based on anti-programmed cell death protein 1 antibody and anti- cytotoxic T-lymphocyte-associated protein 4 antibody and explored the therapeutic potential of faecal microbiota transplantation in combination with ICI therapy in the future.

Indexed as

Gastrointestinal MicrobiomeNeoplasmsFecal Microbiota TransplantationHumansImmune Checkpoint InhibitorsRadioimmunotherapyImmune Checkpoint InhibitorsCytotoxic T-lymphocyte-associated protein 4Faecal microbiota transplantationGut microbiomeImmune checkpoint inhibitors resistanceImmunotherapyProgrammed cell death protein 1/programmed cell death protein ligand 1

Identifiers

PMID34539138
PMCPMC8409158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.